Announcements

Placement of new ordinary shares to fund clinical, regulatory and commercial goals Melbourne, Australia and Baar, Switzerland Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) has successfully raised A$6.3 million via a private placement to international institutional and professional investors ("Placement"). The Placement was conducted at price of A$2.136 per share, representing a 4.3% premium to the 20 day volume weighted average price on April 29 and 15.1% to the closing Price on April 30. There was strong participation in the Placement from institutional investors. The funds raised in the Placement will be used by Clinuvel for an expanded…

Rule 4.7B Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005. Name of entity CLINUVEL PHARMACEUTICALS LIMITED ABN Quarter ended (“current quarter”) 88 089 644 119 31 MARCH 2013 Consolidated statement of cash flows   Cash flows related to operating activities   Current quarter$A’000 Year to date (3 months) $A’000 1.1 Receipts from customers 275 1,138 1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital   (1,066) (15) (1,024) (85) (358)   (2,884) (49) (2,430) (215) (1,111) 1.3 Dividends received 1.4 Interest…

| CEO's Outlook | Historical Perspective - SCENESSE® in EPP | Clinuvel clears manufacturing audit | SCENESSE® data presented at global conferences |

EMA requires more time to review SCENESSE® submission for MAA Melbourne, Australia and Baar, Switzerland Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRADAX: UR9; ADR: CLVLY) today announced that the European Medicines Agency (EMA) has allowed more time to complete the review of Clinuvel’s Marketing Authorisation Application (MAA) under the Centralised Procedure. The EMA procedure, led by the CHMP, will continue at the end of June 2013. Clinuvel filed its MAA for SCENESSE® (afamelanotide 16mg implant) on February 6, 2012 for the preventative treatment of orphan (rare) light intolerance disorder erythropoietic protoporphyria (EPP). “It is not unusual for a first-in-class drug and…